The agreement includes exclusive commercialization in Mexico by Liomont of two biosimilars developed by Oncobiologics.
As part of the deal, Liomont will provide Oncobiologics with upfront licensing and development milestone payments, as well as royalties once the medicines are commercialized.
The deal will see Oncobiologics oversee global clinical trials as well as offer commercial supply manufacturing for launch in the Mexican market.
Liomont CEO Alfredo Rimoch said the partnership is an important step toward introducing high-quality biotherapeutics to Mexico.
"Oncobiologics represents an ideal partner for Liomont’s entry into the biologics market. Together, we believe we can offer Mexican patients affordable therapeutics for serious diseases," Rimoch said.
Oncobiologics founder and CEO Pankaj Mohan said the company is happy to partner with Liomont to bring important biologics to Mexico.
"We are making excellent progress with the development of our biosimilar products and look forward to launching clinical programs very soon," Mohan said.
Mexico-based pharmaceutical company Laboratorios Liomont develops, manufactures, and commercializes Rx and over the counter (OTC) products.